Esomeprazole vs Pantoprazole
## Overview
Esomeprazole offers the highest AUC and greatest acid suppression among first-line PPIs. Pantoprazole has the cleanest drug interaction profile (minimal CYP2C19 inhibition) and widely used IV formulation. This pair best illustrates the efficacy-interaction tradeoff within the PPI class.
## Mechanism of Action
Both are benzimidazole PPIs irreversibly inhibiting parietal cell H+/K+-ATPase. Esomeprazole binds Cys813 and Cys892; pantoprazole binds Cys813 and Cys822.
## Pharmacokinetics
Esomeprazole: S-enantiomer, ~64% bioavailability, CYP2C19 primary. Pantoprazole: ~77% bioavailability, CYP2C19 + CYP3A4, but minimal CYP2C19 inhibitory activity.
## Clinical Considerations
For severe GERD, Zollinger-Ellison syndrome, or refractory ulcers, esomeprazole's superior AUC provides stronger acid suppression. For patients on clopidogrel, antiretrovirals, or other CYP2C19-sensitive drugs, pantoprazole is significantly preferred.
## Key Takeaways
- Esomeprazole: strongest acid suppression; most interactions (CYP2C19)
- Pantoprazole: weaker CYP2C19 inhibition, preferred with clopidogrel, IV available
- Choose based on indication severity and drug interaction profile
结论
Pantoprazole is preferred when drug interactions are a primary concern (clopidogrel, antiretroviral therapy, antifungals). Esomeprazole is preferred for maximum acid suppression in severe GERD or Zollinger-Ellison syndrome.